Personal information

Countries

China

Activities

Collapse all

Employment (1)

Sichuan University West China Hospital: Chengdu, Sichuan, CN

2014-07-01 to present | Professor (State Key Laboratory of Biotherapy)
Employment
Source: Self-asserted source
Hongxin Deng

Education and qualifications (3)

Sichuan University: Chengdu, Sichuan, CN

2004-09-01 to 2008-07-01 | PHD
Education
Source: Self-asserted source
Hongxin Deng

Chengdu Institute of Biology: Chengdu, Sichuan, CN

1998-09-01 to 2001-07-01 | M.S.
Education
Source: Self-asserted source
Hongxin Deng

Nanchang University: Nanchang, Jiangxi, CN

1994-09-01 to 1998-07-01 | B.S
Education
Source: Self-asserted source
Hongxin Deng

Professional activities (1)

American Society of Gene Therapy and Cell Therapy: Milwaukee, Wisconsin, US

2018-11-01 to present
Membership
Source: Self-asserted source
Hongxin Deng

Works (16)

BATF2 prevents glioblastoma multiforme progression by inhibiting recruitment of myeloid-derived suppressor cells.

Oncogene
2021-01-15 | Journal article
DOI: 10.1038/s41388-020-01627-y
PMID: 33452462
PMC: PMC7906906
Source: Self-asserted source
Hongxin Deng

Hypomethylation of GDNF family receptor alpha 1 promotes epithelial-mesenchymal transition and predicts metastasis of colorectal cancer.

PLoS genetics
2020-11-11 | Journal article
DOI: 10.1371/journal.pgen.1009159
PMID: 33175846
PMC: PMC7682896
Source: Self-asserted source
Hongxin Deng

Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.

Theranostics
2020-07-09 | Journal article
DOI: 10.7150/thno.45391
PMID: 32724476
PMC: PMC7381738
Source: Self-asserted source
Hongxin Deng

TFAP2C facilitates somatic cell reprogramming by inhibiting c-Myc-dependent apoptosis and promoting mesenchymal-to-epithelial transition.

Cell death & disease
2020-06-25 | Journal article
DOI: 10.1038/s41419-020-2684-9
PMID: 32587258
PMC: PMC7316975
Source: Self-asserted source
Hongxin Deng

A Novel Antitumor Strategy: Simultaneously Inhibiting Angiogenesis and Complement by Targeting VEGFA/PIGF and C3b/C4b.

Molecular therapy oncolytics
2020-03-27 | Journal article
DOI: 10.1016/j.omto.2019.12.004
PMID: 31909182
PMC: PMC6940616
Source: Self-asserted source
Hongxin Deng

SARI attenuates colon inflammation by promoting STAT1 degradation in intestinal epithelial cells.

Mucosal immunology
2019-06-10 | Journal article
DOI: 10.1038/s41385-019-0178-9
PMID: 31182817
Source: Self-asserted source
Hongxin Deng

Targeted demethylation of the SARI promotor impairs colon tumour growth.

Cancer letters
2019-02-14 | Journal article
DOI: 10.1016/j.canlet.2019.01.040
PMID: 30771439
Source: Self-asserted source
Hongxin Deng

Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy.

Molecular therapy : the journal of the American Society of Gene Therapy
2019-01-02 | Journal article
DOI: 10.1016/j.ymthe.2018.11.010
PMID: 30527756
PMC: PMC6319306
Source: Self-asserted source
Hongxin Deng

Follistatin-like protein 5 inhibits hepatocellular carcinoma progression by inducing caspase-dependent apoptosis and regulating Bcl-2 family proteins.

Journal of cellular and molecular medicine
2018-09-25 | Journal article
DOI: 10.1111/jcmm.13906
PMID: 30255547
PMC: PMC6237577
Source: Self-asserted source
Hongxin Deng

IL-35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells.

Journal of cellular and molecular medicine
2017-11-29 | Journal article
DOI: 10.1111/jcmm.13428
PMID: 29193791
PMC: PMC5783847
Source: Self-asserted source
Hongxin Deng

Human Adipose-Derived Mesenchymal Stem Cell-Secreted CXCL1 and CXCL8 Facilitate Breast Tumor Growth By Promoting Angiogenesis.

Stem cells (Dayton, Ohio)
2017-06-05 | Journal article
DOI: 10.1002/stem.2643
PMID: 28514506
Source: Self-asserted source
Hongxin Deng
grade
Preferred source (of 2)‎

A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity.

Signal transduction and targeted therapy
2016-11-18 | Journal article
DOI: 10.1038/sigtrans.2016.25
PMID: 29263903
PMC: PMC5661645
Source: Self-asserted source
Hongxin Deng

IL-35 Decelerates the Inflammatory Process by Regulating Inflammatory Cytokine Secretion and M1/M2 Macrophage Ratio in Psoriasis.

Journal of immunology (Baltimore, Md. : 1950)
2016-08-15 | Journal article
DOI: 10.4049/jimmunol.1600446
PMID: 27527600
Source: Self-asserted source
Hongxin Deng

SARI inhibits angiogenesis and tumour growth of human colon cancer through directly targeting ceruloplasmin.

Nature communications
2016-06-29 | Journal article
DOI: 10.1038/ncomms11996
PMID: 27353863
PMC: PMC4931276
Source: Self-asserted source
Hongxin Deng

Functional Nanoparticles Activate a Decellularized Liver Scaffold for Blood Detoxification.

Small (Weinheim an der Bergstrasse, Germany)
2016-02-23 | Journal article
DOI: 10.1002/smll.201503320
PMID: 26914158
Source: Self-asserted source
Hongxin Deng

SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.

Clinical cancer research : an official journal of the American Association for Cancer Research
2011-05-27 | Journal article
DOI: 10.1158/1078-0432.ccr-10-3109
PMID: 21622720
Source: Self-asserted source
Hongxin Deng

Peer review (3 reviews for 2 publications/grants)

Review activity for Advanced science. (2)
Review activity for Signal transduction and targeted therapy. (1)
How many people are using ORCID?